:strip_icc()/i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2020/x/5/9SQnZ3SiqgqW9Bn75XtA/2020-11-16t121400z-529170601-rc2c4k9yqkbe-rtrmadp-3-health-coronavirus-vaccines-moderna.jpg)
[ad_1]
Conducted by the National Institute of Health (NIH) in England, an independent study on the duration of antibodies produced by the modern pharmaceutical vaccine Covid-19 showed that the immunity generated lasts at least three months after the second dose.
The researchers tested the level of two antibodies to Covid-19 after the volunteers took both doses of the vaccine and observed a slight and predicted drop in immunity. Even with the expected drop, those vaccinated had higher immunity than those who were not vaccinated and had the coronavirus.
Participants in the English study will now be followed for another 13 months. The objective is to observe how the immunity generated by Moderna’s vaccine will behave in the long term. The expectation is that the duration is greater than the three months already observed.
Published in the “New England Journal of Medicine” on Thursday (3), the study involved 34 volunteers. This is the first independent study on the vaccine by Moderna, which is an American pharmaceutical company.
An end-stage study by the immunizer’s developers reported on day 30 that the vaccine was 94.1% effective, with no serious safety concerns. “The effectiveness of the severe Covid-19 vaccine was 100%,” Moderna said in the publication (read below).
Emergency use of the vaccine
Moderna calls for emergency approval of the Covid vaccine in the US.
On the 30th, the US pharmaceutical company announced that it was requesting authorization for emergency use of its immunizer from the FDA, the US regulatory agency equivalent to Brazil’s Anvisa.
The FDA said it had scheduled a meeting of its vaccine committee to discuss Moderna’s application on Dec. 17.
According to The New York Times, if approved, on December 21, the first Americans will be able to receive this vaccine.
On Thursday, Moderna reported that it plans to make between 100 and 125 million doses of its immunizer available in the first quarter of 2021. In the United States, the expectation is to produce approximately 20 million doses by the end of this year.
The study shows more than 94% effectiveness
Farmacêutica Moderna says its vaccine is 94.5% effective against Covid-19
The phase 3 study, known as the COVE study, conducted by the Moderna laboratory involved more than 30,000 participants. It was based on 196 cases: 185 were participants in the placebo group and 11 in the group that received the vaccine. The only people who became seriously ill (30 participants, including one who died) received the placebo.
“This positive primary analysis confirms the ability of our vaccine to prevent Covid-19 with an effectiveness of 94.1% and, most importantly, its ability to prevent severe Covid-19. We believe that our vaccine will provide a powerful new tool that can change the course of this pandemic and help prevent serious illness, hospitalizations and deaths, ”said Stéphane Bancel, CEO of Moderna.
Understand how Covid vaccine tests work
How the 3 phases work
When testing a vaccine, generally divided into phases 1, 2 and 3, scientists try to identify serious adverse effects and whether the vaccine is capable of inducing an immune response (that is, a response from the body’s defense system).
- STAGES: Why Phase 3 Clinical Trials Are Essential to Your Success and Safety
Phase 1 trials generally involve dozens of volunteers; those of phase 2, hundreds; and phase 3, thousands. These phases are usually carried out separately, but due to the urgency of the pandemic, several companies have taken more than one step at the same time.
- TYPES: The 4 types of vaccines against Covid and what remains to be ready
Before testing in humans, vaccines are tested on animals, usually mice and then monkeys.
